Therapeutic Targeting of RAS Mutant Cancers

Authors:

Brand: Cambridge University Press

ISBN: 9781009073646

107.10 zł

96.39 zł Save 10.71 zł Tax included

Lowest price within 30 days before promotion: 96.39 zł

Quantity

Available in 4-6 weeks

Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.

Product Details

Brand Cambridge University Press

Reference 97901

EAN13 9781009073646

ISBN 9781009073646

Data sheet

Publication date: 2022
Issue number: 1
Cover: paperback
Pages count: 75
Dimensions (mm): 152.00 x 228.00
Weight (g): 80

Introduction; RAS Biology; Oncogenic RAS; RAS Targeting; Downstream Targeting; Upstream Targeting; Targeting Specific RAS Mutants; KRAS G12C Targeting; Direct Targeting of Other RAS Proteins; KRAS G12R Pancreatic Cancer; KRAS G13D Colorectal Cancer; Summary; References.

Comments (0)

Frequently purchased together

No products available

Therapeutic Targeting of RAS Mutant Cancers

Frequently purchased together